Advantages of a genomic DNA-based next-generation sequencing assay for detection of mutant NPM1 measurable residual disease in AML

Advantages of a genomic DNA-based next-generation sequencing assay for detection of mutant NPM1 measurable residual disease in AML

Abstract: Mutations in the nucleophosmin-1 (NPM1) gene are among the most common molecular aberrations in acute myeloid leukemia (AML). Various studies have established mutant NPM1 (mNPM1) as a faithful molecular measurable residual disease (MRD) marker with prognostic significance. Assessment of pr...

Full description

Saved in:
Bibliographic Details
Main Authors: Christian M. Vonk, Tim Grob, Melissa Rijken, François G. Kavelaars, Jolinda M. L. Konijnenburg, Gert J. Ossenkoppele, Markus G. Manz, Violaine Havelange, Yngvar Fløisand, Bob Löwenberg, Peter J. M. Valk
Format: Article
Language:English
Published: Elsevier 2025-03-01
Series:Blood Advances
Online Access:http://www.sciencedirect.com/science/article/pii/S2473952924007043
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items